Clinical study on plasma levels of guanylin and uroguanylin in patients with Crohn disease

doi:10.3877/cma.j.issn.2095-2015.2020.06.003

Abstract

Abstract:

Objective

To evaluate the clinical value of ProGN and ProUGN in patients with Crohn disease(CD).

Methods

The plasma ProGN and ProUGN levels of Crohn disease patients and healthy controls were detected by enzyme-linked immunosorbent assay(ELISA), and the correlation between plasma levels and clinical disease activity and 24-hour stool frequency was analyzed.

Results

Compared with the healthy controls, the plasma ProGN and ProUGN levels of CD patients were significantly lower(P<0.05). Subgroup analysis showed that the plasma ProGN level of patients in remission period and active period was significantly lower than that of healthy control group(P<0.001), while the level of patients in active period was lower than that of patients in remission period, but there was no statistical significance(P=0.121); the plasma ProUGN level of patients in remission period was significantly lower than that in healthy control group(P<0.001), and plasma level of patients in active period was lower than that in healthy control group, but there was no statistical significance(P=0.266), and plasma level of patients in remission period was significantly lower than that in active period(P=0.011). Pearson correlation analysis showed that plasma ProGN and ProUGN levels were negatively correlated with 24-hour stool frequency(r=-0.804, P<0.001; r=-0.767, P<0.001). There was a significant negative correlation between the plasma ProGN level and the Best Crohn disease activity index(r=-0.561, P<0.001), but there was no linear correlation between the plasma ProGN level and the Best Crohn disease activity index(r=-0.155, P=0.314).

Conclusion

The clinical activity and diarrhea may be the determinants for level of proGN in plasma.

Key words: Crohn disease, Guanylin, Uroguanylin

Dongyan Xu, Xiaoyu Zhang, Haijian Zhao, Jian Wang, Jing Sun. Clinical study on plasma levels of guanylin and uroguanylin in patients with Crohn disease[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2020, 10(06): 248-251.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2020.06.003

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2020/V10/I06/248

Figures/Tables 4

References 17

1	洪之武，任建安，黎介寿，等．克罗恩病合并肠瘘273例临床特征与预后分析[J]．中国实用外科杂志，2019,39(5):492-496.
2	Basu N, Arshad N, Visweswariah SS.Receptor guanylyl cyclase C(GC-C)：regulation and signal transduction[J]．Mol Cell Biochem，2010,334:67-80.
3	Moss NG, Fellner RC, Qian X，et al.Uroguanylin，an intestinal natriuretic peptide，is elivered to the kidney as an unprocessedpropeptide[J]．Endocrinology，2008,149:4486-4498.
4	Qian X, MossNG, Fellner RC，et al.Circulating prouroguanylin is processed toits active natriuretic form exclusively within the renal tubules[J]．Endocrinology，2008,149:4499-4509.
5	Wasinger VC, Yau Y, Duo X，et al.Low mass blood peptides discriminative of inflammatory bowel disease(IBD)severity：a quantitative proteomic perspective[J]．Mol Cell Proteomics，2016,15:256-265.
6	中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]．中华炎性肠病杂志，2018,2(3):173-190.
7	Dye FS, Larraufie P, Kay R，et al.Characterisation of proguanylin expressing cells in the intestine-evidence for constitutive luminal secretion[J]．Sci Rep，2019,9:15574.
8	Brenna O, Bruland T, Furnes MW，et al.The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease[J]．Scand J Gastroenterol，2015,50:1241-1252.
9	Han XN, Mann E, Gilbert S，et al.Loss of guanylyl cyclase C(GCC)signaling leads to dysfunctional intestinal barrier[J]．Plos One，2011,6:e16139.
10	Wu F, Zhang SM, Dassopoulos T，et al.Identification of MicroRNAs Associated with Ileal and Colonic Crohn′s Disease[J]．Inflammatory Bowel Dis，2010,16:1729-1738.
11	Brenna O, Furnes MW, Munkvold B，et al.Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa[J]．Cell Tissue Res，2016,365:331-341.
12	Brierley SM.Guanylate cyclase-C receptor activation：unexpected biology[J]．Curr Opin Pharmacol，2012,12:632-640.
13	Priyamvada S, Gomes R, Gill RK，et al.Mechanisms underlying dysregulation of electrolyte absorption in inflammatory bowel disease-associated diarrhea[J]．Inflamm Bowel Dis，2015,21:2926-2935.
14	Lan D, Niu J, Miao J，et al.Expression of guanylate cyclase-C，guanylin，and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index[J]．Sci Rep，2016,6:25034.
15	Fellner RC, Moss NG, Goy MF.Dietary salt regulates uroguany-lin expression and signaling activity in the kidney，but not in the intestine[J]．Physiol Rep，2016,4:e12782.
16	Qian X, Moss NG, Fellner RC，et al.The rat kidney contains high levels of prouro-guanylin(the uroguanylin precursor)but does not express GC-C(the enteric uroguanylin receptor)[J]．Am J Physiol Renal Physiol，2011,300:F561-573.
17	Valentino MA, Lin JE, Snook AE，et al.Auroguanylin-GUCY2C endocrine axis regulates feeding in mice[J]．J Clin Invest，2011,121:3578-3588.

项目	ProGN	ProUGN
克罗恩病患者(n＝44)	5.24±0.39	2.26±0.42
健康对照组(n＝20)	7.68±0.36	2.62±0.41
t值	-23.69	-3.194
P值	<0.001	0.002

项目	ProGN	ProUGN
克罗恩病患者(n＝44)	5.24±0.39	2.26±0.42
健康对照组(n＝20)	7.68±0.36	2.62±0.41
t值	-23.69	-3.194
P值	<0.001	0.002

[1]	Weili Wang, Wenjie Cheng, Yanling Wen, Xiang Gao, Min Zhi, Junli Yu, Yao Chen, Xiaoyin Liu, Guangjian Liu. Contrast-enhanced ultrasound quantitative analysis for assessment of disease activity of Crohn′s disease [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2019, 16(12): 949-955.
[2]	Shuping Wei, Bin Yang, Chaoli Xu, Yousheng Li, Qi Mao, Ninghua Fu, Fuli Tian. Application of conventional ultrasound and contrast-enhanced ultrasound in the diagnosis of Crohn′s disease [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2016, 13(06): 406-410.
[3]	Zhiyuan Weng, Xue Xiao, Youxiang Zhang. Color Doppler Ultrasound Diagnosis of Crohn Disease in Children [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2014, 10(06): 801-803.
[4]	Wenjian Meng, Yufang Wang, Ziqiang Wang. Experience and lessons of diagnosis and treatment on one case of active complex Crohn disease [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(04): 340-344.
[5]	Litian Wang, Lisheng Yang, Gang Liu. Progress in study of microRNA in inflammatory bowel disease [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(03): 230-233.
[6]	Jiali Yu, Xueliang Jiang. Application progress of biological agents from the perspective of therapeutic strategy transformation of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(03): 129-134.
[7]	Wensong Ge. By improving the level of early diagnosis and treatment of Crohn disease in order to improve the curative effect and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2021, 11(01): 28-30.
[8]	Zhi Li, Wensong Ge. Benefits and risks of drug combination therapy for inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2019, 09(05): 193-195.
[9]	Li Chen, Fengshang Zhu, Changqing Yang. Several hot issues in the current diagnosis and treatment of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2019, 09(03): 97-99.
[10]	Danping Yin, Tongting Liu. Recent advances in differential diagnosis of Crohn disease and intestinal tuberculosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2017, 07(02): 79-82.
[11]	Xin Ma, Meng Jin, Huijuan Ning, Wenwen Liu, Youzhe Gong, Yanling Zhang, Xuemei Zhong. Application of small intestinal capsule endoscopy in children with Crohn′s disease [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(03): 185-189.

Please choose a citation manager

Content to export